A novel plasmid-based reverse genetics system allows for efficient intracellular reconstitution of influenza A virus RNP complexes, providing a convenient alternative to RNP transfection.
Answers are grounded in this paper and cite their sources.
May streamline recombinant influenza virus generation in labs; leaves open broader validation for pathogenesis or vaccine studies.
A reverse genetics system for negative-strand RNA viruses was first successfully developed for influenza viruses. This technology involved the transfection of in vitro-reconstituted ribonucleoprotein (RNP) complexes into influenza virus-infected cells. We have now developed a method that allows intracellular reconstitution of RNP complexes from plasmid-based expression vectors. Expression of a viral RNA-like transcript is achieved from a plasmid containing a truncated human polymerase I (polI) promoter and a ribozyme sequence that generates the desired 3' end by autocatalytic cleavage. The polI-driven plasmid is cotransfected into human 293 cells with polII-responsive plasmids that express the viral PB1, PB2, PA, and NP proteins. This exclusively plasmid-driven system results in the efficient transcription and replication of the viral RNA-like reporter and allows the study of cis- and trans-acting signals involved in the transcription and replication of influenza virus RNAs. Using this system, we have also been able to rescue a synthetic neuraminidase gene into a recombinant influenza virus. This method represents a convenient alternative to the previously established RNP transfection system.
No takes yet. Share an insight, caveat, or question.
Pleschka et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: